Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 4, 2012, Pages 376-381

  Best, Brookie M ^a,b   Letendre, Scott L ^c   Koopmans, Peter ^d   Rossi, Steven S ^b   Clifford, David B ^e   Collier, Ann C ^f   Gelman, Benjamin B ^g   Marra, Christina M ^f   McArthur, Justin C ^h   McCutchan, J Allen ^c   Morgello, Susan ⁱ   Simpson, David M ⁱ   Capparelli, Edmund V ^a,b   Ellis, Ronald J ^j   Grant, Igor ^k  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

CSF; Pharmacokinetics; Tenofovir

Indexed keywords

TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; DRUG PENETRATION; FEMALE; HUMAN; IC 50; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADENINE; ADULT; COHORT STUDIES; FEMALE; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84859744786     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318247ec54     Document Type: Article

References (47)

1. Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS. 2002;16(suppl 4):S61-S68. (Pubitemid 36278928)
2. Langford TD, Letendre SL, Larrea GJ, et al. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2003;13:195-210. (Pubitemid 36460820)
3. Ances BM, Clifford DB. HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep. 2008;8:455-461.
4. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136-142. (Pubitemid 34520894)
5. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 24:1243-1250.
6. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-593. (Pubitemid 34177896)
7. De Luca A, Ciancio BC, Larussa D, et al. Correlates of independent HIV- 1 replication in the CNS and of its control by antiretrovirals. Neurology. 2002;59:342-347. (Pubitemid 34857925)
8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295. (Pubitemid 27495741)
9. Reddy YS, Kashuba A, Gerber J, et al. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses. 2003;19:167-176. (Pubitemid 36359881)
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
11. Jullien V, Treluyer JM, Rey E, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49:3361-3366. (Pubitemid 41060583)
12. Kiser JJ, Aquilante CL, Anderson PL, et al. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIVinfectedpatients. J Acquir Immune Defic Syndr. 2008;47:298-303. (Pubitemid 351619414)
13. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739. (Pubitemid 32906664)
14. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42:2380-2384. (Pubitemid 28420382)
15. van Gelder J, Deferme S, Naesens L, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos. 2002;30:924-930. (Pubitemid 34815423)
16. Viread. [package insert]. Foster City, CA: Gilead Sciences, Inc; 2010.
17. Simpson DM. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clin Infect Dis. 1999;29:19-34. (Pubitemid 29336797)
18. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
19. Strazielle N, Ghersi-Egea JF. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol. 2005;15:105-133. (Pubitemid 40343194)
20. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 2006;3:1.
21. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304. (Pubitemid 44527501)
22. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71:619-627. (Pubitemid 46147926)
23. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011; 91:852-858.
24. Mallants R, Van Oosterwyck K, Van Vaeck L, et al. Multidrug resistance- associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica. 2005;35:1055-1066. (Pubitemid 43068047)
25. Ray AS, Cihlar T. Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events. J Infect Dis. 2007;195:1389-1390. (Pubitemid 46649628)
26. Gazzin S, Strazielle N, Schmitt C, et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between bloodbrain interfaces. J Comp Neurol. 2008;510:497-507.
27. Storch CH, Theile D, Lindenmaier H, et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573-1581. (Pubitemid 46527547)
28. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009;82:A99-A109.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011: 1-166. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf.Accessed August 9, 2011.
30. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005;41:1787-1793. (Pubitemid 41759866)
31. Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother.2005;49:2504-2506. (Pubitemid 40734489)
32. Videx EC. [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
33. Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses. 2000;16: 1491-1502.
34. Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17: 235-238.
35. Burger DM, Kraayeveld CL, Meenhorst PL, et al. Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci. 1995;17: 218-221.
36. Haas DW, Stone J, Clough LA, et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther. 2000;68: 367-374.
37. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009;23:83-87.
38. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS. 2005;19:949-952. (Pubitemid 40834938)
39. Nagle MA, Truong DM, Dnyanmote AV, et al. Analysis of threedimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem. 2011;286: 243-251.
40. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
41. Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267-272. (Pubitemid 46569912)
42. Burchett SK, Best B, Mirochnick M, . Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at: 14th Conferenceon Retroviruses and Opportunistic Infections; February 28, 2007; Los Angeles, CA.
43. Lowe SH, van Leeuwen E, Droste JA, et al. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosineplus tenofovir containing antiretroviral regimen. Ther Drug Monit. 2007;29:566-570. (Pubitemid 47494053)
44. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899-1907. (Pubitemid 47329766)
45. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving longterm highly active antiretroviral therapy. Clin Infect Dis. 2008;46: 719-725. (Pubitemid 351321556)
46. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol. 2011;201:29-104.
47. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance of physiology for drug therapy. Handb Exp Pharmacol. 2011;201: 299-323.